

Referenties: Nieuwe antidiabetica

Incretinemimetica

- <http://www.apb.be/SiteCollectionDocuments/MEDICAMENTS%20ET%20SOINS%20PHARMACEUTIQUES/BONNES%20PRATIQUES%20EN%20OFFICINE%20-%20APOTHEEKRICHTLIJNEN/DIABETE%20T2/FT-2013-01-Diabetes-en-Ramadan.pdf>
- *Gecommentarieerd geneesmiddelenrepertorium, 2017*
- 'Diabetes en ramadan: achtergrond en praktische aanbevelingen', *Farmaceutisch tijdschrift voor België*, maart 2013
- http://www.inami.fgov.be/SiteCollectionDocuments/consensus_literatuur_samenvatting_20161117.pdf
- http://jpma.org.pk/full_article_text.php?article_id=7805
- *Juris J. Meier, GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus, Nature, volume 8, 2012, 728-742.*
- *Terugbetaling: Tarief APB*
- *Flint et al., Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide., British Journal of Clinical Pharmacology, 70:6, 2010, 807-814*
- *Davies et al., Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial, Diabetes Care, december 2015, 1-9*
- *Jacobsen et al., Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide, British Journal of Clinical Pharmacology, 68:6, 2009, 898-905*
- *Monami M et al. Safety issues with glucagon-like peptide-1 receptor agonists: pancreatitis, pancreatic cancer, and cholelithiasis. data from randomised controlled trials. Diabetes Obes Metab. 2017 Feb 28.*
- *R Holman, et al. EXenatide Study of Cardiovascular Event Lowering (EXSCEL): primary results. EASD 2017. Session S29.*
- *Ipsa, Masterclass: Farmacologie van de antidiabetica, 2015*
- www.pharmaplanet.be/nl/node/52055?token=fC2sWgKeScUnYUtzGja5&utm_campaign=1117808451&utm_content=1122613298954&utm_medium=Pharmaplanet&utm_source=Emailvision
- *Contact firma's : GSK, Eli Lilly, Novo Nordisk, Astra Zeneca, Sanofi Belgium*

Gliptinen

- *Folia 2013.*
- <http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf>
- *Safety of DDP-4 inhibitors for treating type 2 diabetes, André J Scheen in Expert Opin. Drug Saf. (2015) 14(4).*
- *Berhan A, Berhan Y. Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. BMC Endocr Disord 2013;13:9.*

- *Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.* Verma S¹, Goldenberg RM¹, Bhatt DL¹, Farkouh ME¹, Quan A¹, Teoh H¹, Connelly KA¹, Leiter LA¹, Friedrich JO¹. *CMAJ Open.* 2017 Feb 24;5(1):E152-E177.
- *Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.* Pollack PS¹, Chadwick KD², Smith DM³, Billger M⁴, Hirshberg B⁵, Iqbal N¹, Boulton DW⁶.
- *Cardiovasc Diabetol.* 2017 Sep 13;16(1):113.
- *Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin : a retrospective observational pharmacy claims analysis. Diabetes Care* 2010; 33:2349.
- *The Electronic Medicines Compendium : Galvus 50 mg tablets*
http://emc.medicines.org.uk/medicine/20734/SPC/Galvus+50+mg+Tablets/#CLINICAL_PRECAUTIONS
- <https://medicijnbalans.nl/nieuws/51219>

Gliflozinen

- www.apb.be/SiteCollectionDocuments/MEDICAMENTS%20ET%20SOINS%20PHARMACEUTIQUES/BONNES%20PRATIQUES%20EN%20OFFICINE%20-%20APOTHEEKRICHTLIJNEN/DIABETE%20T2/FT-2013-01-Diabetes-en-Ramadan.pdf
- Gecommentarieerd geneesmiddelenrepertorium, 2017.
- 'Diabetes en ramadan: achtergrond en praktische aanbevelingen', Farmaceutisch tijdschrift voor België, maart 2013.
- *Terugbetaling: Tarief APB.*
- JASN: "Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects,"
<http://jasn.asnjournals.org/>
- <https://www.farmaka.be/frontend/files/publications/files/diabetes-mellitus-type-2-presentatie.pdf>
- www.bcfi.be/nl/articles/2686?folia=2683
- Salem A Beshyah et al., Use of SGLT2-inhibitors during Ramadan: a survey of physicians' views and practical guidance., *The British journal of diabetes*, Volume 16, issue 1, 20-24.
- Koeck PH, Bastiaens H, Benhalima K, Cloetens H, Feyen L, Koeck P, Sunaert P, Van Crombrugge P, Van Pottelbergh I, van Leeuwen E, Verhaegen A, Nobels F. Richtlijn voor goede medische praktijkvoering: Diabetes mellitus type 2. Antwerpen: Domus Medica; 2015.
- www.ema.europa.eu/docs/en_GB/document_library/Press_release/2017/02/WC500222191.pdf
- www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/evidenceexpert.ShowDrugInteractionsResults
- www.leicestershirediabetes.org.uk/uploads/documents/480%20Religious%20fasting,%20Ramadan%20and%20hypoglycemia%20in%20people%20with%20diabetes.pdf.
- www.medi-sphere.be/nl/actualiteit/hoe-de-evolutie-van-diabetische-nefropathie-afremmen?utm_source=MarketingCloud&utm_campaign=eMS+Apr3A+NL&utm_medium=Email&utm_content=

- McGovern A et al. Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use. *Diabetes Ther.* 2017;8(2):365-376.
- Ipsa, e-learning canagliflozin.
- Neal MB et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med.* 2017 Jun 12.
- www.fda.gov/downloads/Drugs/DrugSafety/UCM461790.pdf
- R Eldor, et al. Safety and efficacy of ertugliflozin after 52 weeks in patients with type 2 diabetes inadequately controlled on metformin and sitagliptin: VERTIS SITA2 trial extension. EASD 2017. Session OP 07: SGLT2 inhibitors: clinical utility.
- P Hollander, et al. Safety and efficacy of ertugliflozine compared to glimepiride in patients with type 2 diabetes inadequately controlled on metformin: the VERTIS SU trial. EASD 2017. Session OP 07: SGLT2 inhibitors: clinical utility.
- Wilding J., et al. Positioning SGLT2 Inhibitors/Incretin-based therapies in the treatment algorithm. *DiabetesJournals.org.* Aug. 2016
- Wilding, John P.H. The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. *Metabolism - Clinical and Experimental* , Volume 63 , Issue 10 , 1228 – 1237.
- <http://www.bcfi.be/nl/articles/2765?folia=2762>
- <http://www.bcfi.be/nl/articles/2767?folia=2762>
- D. Hira, T. Terada, BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical.
- Implications, *Biochem. Pharmacol.* (2017).
- <http://circ.ahajournals.org/content/early/2017/05/16/CIRCULATIONAHA.117.029190>
- Contact firma's: Janssen-Cilag, Astra-Zeneca, Boehringer Ingelheim.